A decent Company Secretary is never redundant for this type of company. How/Why do you think BOD 1 got into so much hot water.
I don't buy Chris' story regarding Altura - not that he should care. He would have been in the spotlight had he stayed to hand over a project that reached nameplate in such a short period of time. I'm not convinced this move was best for him or for Birimian. Only time will tell and I hope I am wrong.
In my view it is far more important for the project sponsor (MD) to have geographic experience than it is to have technical experience. If you can get both, even better.
I wish Chris and his team success, obviously, but I have a nagging concern that the failings of Altura, which are only being identified now, may not have been known by Chris n Co before they left. In other words, they may wish to copy across to Goulamina what they think works from Altura. This sudden interest in HPGR technology may be a case in point. To early to make any definitive statement though.
- Forums
- ASX - By Stock
- FFX
- Re-Rating: General Lithium & Mali Lithium
Re-Rating: General Lithium & Mali Lithium, page-223
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online